Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 11/20 | 0.47 |
| ▸ | ITGA2B | P08514 | 11/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.46 |
| ▸ | GNAI3 | P08754 | 2/20 | 0.45 |
| ▸ | GNAO1 | P09471 | 2/20 | 0.45 |
| ▸ | GNAI1 | P63096 | 2/20 | 0.45 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.44 |
| ▸ | TPSD1 | Q9BZJ3 | 1/20 | 0.44 |
| ▸ | TPSG1 | Q9NRR2 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17664591 | 0.84 | FAAH (0.50) | FAAHGLA | |
| SCHEMBL485662 | 0.83 | FAAH (0.44) | ITGB3ITGA2BFAAHGNAI3GNAO1 | |
| SCHEMBL23567684 | 0.81 | FAAH (0.60) | FAAHGLA | |
| SCHEMBL9579341 | 0.81 | ITGB3 (0.43) | ITGB3ITGA2BFAAHGNAI3GNAO1 | |
| SCHEMBL9579270 | 0.79 | FAAH (0.44) | ITGB3ITGA2BFAAHGNAI3GNAO1 | |
| SCHEMBL18402581 | 0.79 | FAAH (0.44) | ITGB3ITGA2BFAAHGNAI3GNAO1 | |
| SCHEMBL5645399 | 0.79 | EPHX1 (0.50) | ITGB3ITGA2BGNAI3GNAO1GNAI1 | |
| SCHEMBL16311956 | 0.79 | ITGB3 (0.49) | ITGB3ITGA2BFAAHGNAI3GNAO1 | |
| Hydrochloric Acid SCHEMBL7423753 | 0.77 | EPHX1 (0.49) | ITGB3ITGA2BGNAI3GNAO1GNAI1 | |
| SCHEMBL14767446 | 0.77 | FAAH (0.48) | ITGB3ITGA2BFAAHGNAI3GNAO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7183415-B2 | Quinoline compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-02-27 | — | — | US | disclosed |
| US-20050209213-A1 | Quinoline compound | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| CN-1585751-A | Quinoline compound | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2005-02-23 | — | — | CN | disclosed |
| EP-1447402-A1 | QUINOLINE COMPOUND | Takeda Chemical Industries, Ltd. (JP) | 2004-08-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209213-A1 | Quinoline compound | MC1R, MC2R, TYR | ITGB3 4538/4885ITGA2B 4451/4885FAAH 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.